Cyclerion Therapeutics (NASDAQ:CYCN) Shares Up 2% – Still a Buy?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) shares were up 2% on Wednesday . The stock traded as high as $3.08 and last traded at $3.06. Approximately 111,689 shares traded hands during trading, a decline of 99% from the average daily volume of 14,278,410 shares. The stock had previously closed at $3.00.

Cyclerion Therapeutics Price Performance

The stock’s fifty day simple moving average is $2.15 and its 200-day simple moving average is $1.82. The stock has a market cap of $13.25 million, a P/E ratio of -2.64 and a beta of 0.89.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its earnings results on Monday, March 30th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.19. Cyclerion Therapeutics had a negative return on equity of 39.23% and a negative net margin of 170.11%.The company had revenue of $1.03 million during the quarter, compared to the consensus estimate of $0.10 million. Analysts forecast that Cyclerion Therapeutics, Inc. will post -1.2 EPS for the current year.

Institutional Investors Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics at the end of the most recent quarter. Institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.